Isoniazid for preventing tuberculosis in HIV-infected children

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 8, 2017, Pages

  Zunza, Moleen ^a   Gray, Diane M ^b   Young, Taryn ^a,c   Cotton, Mark ^d   Zar, Heather J ^e  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b RED CROSS WAR MEMORIAL CHILDREN S HOSPITAL   (South Africa)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ISONIAZID; PLACEBO; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COTRIMOXAZOLE; TUBERCULOSTATIC AGENT;

ANEMIA; ANTIRETROVIRAL THERAPY; BOTSWANA; CHILD; CHILD DEATH; DRUG SAFETY; HEMATOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTICENTER STUDY (TOPIC); NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOUTH AFRICA; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TUBERCULOSIS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; HIV INFECTIONS; INCIDENCE; MORTALITY; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CHILD; HIV INFECTIONS; HUMANS; INCIDENCE; ISONIAZID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 85028530822     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006418.pub3     Document Type: Review

References (60)

1. Gray DM, Workman LJ, Lombard CJ, Jennings T, Innes S, Grobbelaar CJ, et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease 2014;18(3):322-7. 3229236
2. Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. New England Journal of Medicine 2011;365(1):21-31. 3229238
3. Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet 2007;334:136-42. 3229240
4. Frigati LJ, Kranzer K, Cotton MF, Schaaf HS, Lombard CJ, Zar HJ. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting. Thorax 2011;66(6):496-501. 6616441
5. Hesseling AC, Kim S, Madhi S, Nachman S, Schaaf HS, Violari A, et al. High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial. International Journal of Tuberculosis and Lung Disease 2012;16(2):192-5. 3229244
6. Iro MA, Brown N. Isoniazid prophylaxis started at 3-4 months of life does not prevent tuberculosis disease or infection in both HIV-infected and uninfected children. Archives of Disease in Childhood: Education and Practice Edition 2013;98(1):40. 6616442
7. le Roux SM, Cotton MF, Golub JE, le Roux DM, Workman L, Zar HJ. Adherence to isoniazid prophylaxis among HIV-infected children: a randomized controlled trial comparing two dosing schedules. BMC Medicine 2009;7(67):1-13. 6616443
8. le Roux SM, Cotton MF, Myer L, le Roux DM, Schaaf HS, Lombard CJ, et al. Safety of long-term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules. International Journal of Tuberculosis and Lung Disease 2013;17(1):26-31. 6616444
9. Marais BJ, Graham SM, Maeurer M, Zumla A. Progress and challenges in childhood tuberculosis. Lancet. Infectious Diseases 2013;13(4):287-9. 6616445
10. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent infection in HIV infected persons. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD000171.pub3]
11. Berggren Palme I, Gudetta B, Bruchfield J, Muhe L, Giesecke J. Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome and survival in a cohort of Ethiopian children with tuberculosis. Pediatric Infectious Disease Journal 2002;21:1053-61.
12. Burman WJ. Issues in the management of HIV-related tuberculosis. Clinics in Chest Medicine 2005;26:283-94.
13. Chintu C, Mwaba P. Tuberculosis in children with human immunodeficiency virus infection. The International Journal of Tuberculosis Lung Disease 2005;9(5):477-84.
14. Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis co-infected populations. Proceeding of the National Academy of Sciences of the United States of America 2006;103(18):7042-7.
15. Deeks J, Higgins JP, Altman D. Chapter 9: Analysing data and undertaking meta-analysis. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons, 2008:243-96.
16. Donald PR. Childhood tuberculosis. Current Opinion in Pulmonary Medicine 2000;6:187-92.
17. Donald PR. Childhood tuberculosis: out of control?. Current Opinion in Pulmonary Medicine 2002;8:178-82.
18. Edmonds A, Lusiama J, Napravnik S, Kitetele F, Van Rie A, Behets F. Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children. International Journal of Epidemiology 2009;38:1612-21.
19. Foster K, Alton H. Chronic lung infection in children. Paediatric Respiratory Reviews 2003;4:225-9.
20. Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, et al. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS 2010;24(5):S57-65.
21. Goletti D, Weisman D, Jackson RW, Graham NM, Vlahov D, Klein RS, et al. Effect of mycobacterium tuberculosis on HIV replication: role of immune activation. Journal of Immunology 1996;157:1271-8.
22. GRADE Working Group, McMaster University. GRADEpro GDT. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
23. Grant AD, Charalambous S, Fielding KL, Day JH, Corbertt EL, Chaisson RE, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa. JAMA 2005;293(22):2719-25.
24. Gray D, Nuttall J, Lombard C, Davies MA, Workman L, Apolles P, et al. Low rates of hepatotoxicity in HIV-infected children on anti-retroviral therapy with and without isoniazid prophylaxis. Journal of Tropical Pediatrics 2010;56(3):159-65.
25. Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
26. Hesseling AC, Westra AE, Werschkull H, Donald PR, Beyers N, Hussey GD, et al. Outcome of HIV infected children with culture confirmed tuberculosis. Archives of Disease in Childhood 2005;90:1171-4.
27. Hesseling AC, Cotton MF, Jennings T, Whitelaw A, Johnson LF, Eley B, et al. High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies. Clinical Infectious Diseases 2009;48:108-14.
28. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
29. Ikeogu Mo, Wolf B, Mathe S. Pulmonary manifestations in HIV seropositivity and malnutrition in Zimbabwe. Archives of Disease in Childhood 1997;76:124-8.
30. Jeena PM, Coovadia HM, Thula SA, Blythe D, Buckels NJ, Chetty R. Persistent and chronic lung disease in HIV-1-infected and uninfected African children. AIDS 1998;12:1185-93.
31. Jeena PM, Pillay P, Pillay T, Coovadia HM. Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. The International Journal of Tuberculosis and Lung Disease 2002;6:672-8.
32. Kochi A. The global tuberculosis situation and the new strategy of the World Health Organisation. Tubercle 1991;72:1-6.
33. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
34. Martinson NA, Moultrie H, van Niekerk R, Barry G, Coovadia A, Cotton M, et al. HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort. International Journal of Tuberculosis and Lung Disease 2009;13(7):862-7.
35. Mukadi YD, Wiktor Z, Coulibaly IM, Coulibaly D, Mbengue A, Folquet AM, et al. Impact of HIV infection on the development, clinical presentation and outcome of tuberculosis among children in Abidjan, Cote d'Ivoire. AIDS 1997;11(9):1151-8.
36. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. American Journal of Respiratory and Critical Care Medicine 1998;158(1):157-61.
37. Nelson LJ, Wells CD. Global epidemiology of childhood tuberculosis. The International Journal of Tuberculosis and Lung Disease 2004;8(5):636-47.
38. U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, 2014. https://rsc.tech-res.com/docs/default-source/safety/daids_ae_grading_table_v2_nov2014.pdf?sfvrsn=8 (accessed 03 July 2017).
39. Perriens JH, St Louis ME, Mukadi YB, Brown C, Prignot J, Pouthier F, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. New England Journal of Medicine 1995;332(12):779-84.
40. Puthanakit T, Oberdorfer P, Akarathum N, Wannarit P, Sirisanthana T, Sirianthana V. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected Thai children. Pediatric Infectious Disease Journal 2006;25(1):53-8.
41. Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis:a randomised double-blind, placebo-controlled trial. Lancet 2014;384(9944):682-90.
42. Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. Journal of Acquired Immune Deficiency Syndromes 2008;47:566-9.
43. Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, et al. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. Journal of Acquired Immune Deficiency Syndromes 2009;50:439-43.
44. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
45. Schaaf HS, Geidenduys A, Gie RP, Cotton MF. Culture-positive tuberculosis in human immunodeficiency virus type-1-infected children. Pediatric Infectious Disease Journal 1998;7:599-604.
46. Schaaf HS, Krook S, Hollemans DW, Warren RM, Donald PR, Hesseling AC. Recurrent culture-confirmed tuberculosis in human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal 2005;24(8):685-91.
47. Smieja MJ, Marchettu CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database of Systematic Reviews 1999, Issue 1. [DOI: 10.1002/14651858.CD001363]
48. Smith K, Kuhn L, Coovadia A, Meyers T, Hub CC, Reitz C, et al. Immune reconstitution inflammatory syndrome among HIV infected South African infants initiating antiretroviral therapy. AIDS 2009;23(9):1097-107.
49. UNAIDS/WHO. AIDS epidemic update. September. www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/201309_epi_core_en.pdf (accessed 25 November 2013).
50. Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff MW, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. American Journal of Respiratory and Critical Care Medicine 2005;171:1430-5.
51. Walters E, Cotton MF, Rabie H, Schaaf HS, Walters LO, Marais BJ. Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy. BMC Pediatrics 2008;8:1.
52. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. American Journal of Respiratory and Critical Care Medicine 1995;151:129-35.
53. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach: 2010 revision. www.who.int/hiv/pub/paediatric/infants2010/en/index.html (accessed 16 November 2015).
54. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. www.whqlibdoc.who.int/publications/2011/9789241500708_eng.pdf (accessed 16 November 2015).
55. World Health Organization. Global Tuberculosis Report, 2012. apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf (accessed June 2013).
56. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, 2013. www.who.int/hiv/pub/guidelines/arv2013/download/en/ (accessed prior to 6 June 2017).
57. Zampoli M, Kilborn T, Eley B. Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children. International Journal of Tuberculosis and Lung Disease 2007;11(4):417-23.
58. Zar HJ, Manslo D, Tannebaum E, Klein M, Argent A, Eley B, et al. Aetiology and outcome of pneumonia in human immunodeficiency virus-infected children hospitalized in South Africa. Acta Paediatrica 2001;90(2):119-25.
59. Gray DM, Zar HJ, Cotton M. The impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD006418]
60. Gray DM, Young T, Zar H, Cotton M. Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD006418.pub2]